I agree with you here. For memory Dr Grossman did say early on things were going to plan. But, common sense here, we know it's a complex trial and regardless the spike in cases. Rem_l is for patients on ventilators and the difficult part is convincing them to participate on trial.
investors can argue the company needs to inform shareholders of current situation.
Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-707
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
-0.038(3.33%) |
Mkt cap ! $1.255B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.08 | $5.610M | 5.063M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 59342 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 96264 | 22 |
View Market Depth
| Last trade - 14.27pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |